News

Merkel Cell Carcinoma and Melanoma: Trends and Survival in the United States

Priority Review Granted by FDA for RP1 Plus Nivolumab in Advanced Melanoma

C-POST Trial: Cemiplimab-rwlc After Surgery for High-Risk Squamous Cell Skin Cancer

ATLAS: A New Mnemonic for Symptoms Linked to Melanoma Recurrence

Can Focused Ultrasound Improve Immunotherapy Response in Melanoma? Pilot Study Intends to Find Out

Intradermal Injection of Axitinib Being Tested in Nonmelanoma Skin Cancers

For Advanced Squamous Cell Skin Cancer: FDA Approves PD-L1–Blocking Antibody

Epigenetic Work Reveals Potential Biomarker in Cutaneous Melanoma

Under Study in Squamous Cell Skin Cancer: Neoantigen Therapy Plus Pembrolizumab

Investigating Immunotherapy Resistance in Merkel Cell Carcinoma

Immune Biomarkers as Predictors of Survival and Risk in Patients With Melanoma

Immunotherapy Combination Under Study in High-Risk Resectable Melanoma

Advanced Merkel Cell Carcinoma: How Effective Is Immunotherapy Rechallenge?

SITC 2024: Predicting Recurrence With ctDNA Biomarker in High-Risk Melanoma

Is HPV Associated With Hand Squamous Cell Carcinoma?

SITC 2024: Update on Use of HDAC Inhibitor Plus Nivolumab in Advanced Melanoma

SITC 2024: Addition of Radiotherapy to Immunotherapy in Advanced Merkel Cell Carcinoma

SITC 2024: Comparing Types of Tumor Infiltrating Lymphocytes in Merkel Cell Carcinoma

Does Skin Screening Alter the Incidence of Skin Cancer? Australian Researchers Weigh In

SITC 2024: Potential Biomarker of Disease Progression After Immunotherapy for Advanced Melanoma

SITC 2024: Efficacy Outcomes With TIL Therapy for Advanced Melanoma

Radiotherapy for Merkel Cell Carcinoma: Hypofractionated vs Standard Fractionation

Pediatric Cutaneous Melanoma: Recommendations for Diagnosis and Treatment

Is Immunotherapy Efficacious for Children and Adolescents With Melanoma?

Calculating Risk of Dermatologic Concerns After Solid Organ Transplantation

Surgical Strategies for Melanoma: Listening to the Patient Voice

Does Radiation Therapy for Thyroid Cancer Increase the Risk of Skin Cancers?

Treatment Resistance in Melanoma: Are Biological Sex Differences at Play?

Can Teledermatology Improve Time to Diagnosis Among Chilean Patients With Skin Cancer?

Does Age Impact Recurrence After Image-Guided Superficial Radiotherapy for Skin Cancers?

Does Low-Count Monoclonal B-Cell Lymphocytosis Increase the Risk of Melanoma?

What’s in a Name? ‘Keratinocyte Cancer’ or ‘Non-Melanoma Skin Cancer’

Does Adjuvant Therapy Impact Overall Survival in Stage III Melanoma?

ESMO 2024: Long-Term Survival Update for INMC Pooled Analysis of Neoadjuvant Therapy in Melanoma

ESMO 2024: Hypomethylation Plus Immune Checkpoint Inhibition for Metastatic Melanoma

Are U.S. Veterans at Risk for Developing Skin Cancer? Researchers Investigate

ESMO 2024: 10-Year Outcomes With Pembrolizumab vs Ipilimumab in Advanced Melanoma

Mohs Micrographic Surgery in High-Risk Basal Cell Carcinoma

ESMO 2024: Immune Checkpoint Inhibition Following Targeted Therapy for Advanced Melanoma

ESMO 2024: Final Results From CheckMate 067 of Nivolumab Plus Ipilimumab in Advanced Melanoma

ESMO 2024: Sotigalimab Plus Pembrolizumab in Metastatic Melanoma

Effects of UVA vs UVB Exposure on Melanoma Risk

Long-Term Health-Related Quality of Life With Adjuvant Pembrolizumab in Stage III Melanoma

Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors

BRAF-Mutated Metastatic Melanoma: Predicting Therapeutic Response With ctDNA

Early Results of Combination Regimens With Pembrolizumab in Melanoma

4-Year Follow-up on Lenvatinib Plus Pembrolizumab in Advanced Melanoma

Can FDG-PET Predict Survival and Response to Neoadjuvant Immunotherapy in Melanoma?

Role of Cancer Cell Plasticity in Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma

Nivolumab Plus Relatlimab in Melanoma: 3-Year Survival Outcomes From RELATIVITY-047

MEK Inhibitor in NRAS-Mutated Melanoma: Phase II Trial Update

Lifetime Prevalence of Skin Cancer and Sexual Orientation: Differences by Race and Ethnicity?

Novel Immunotherapy Combination After Anti–PD-1 Therapy Fails in Advanced Melanoma

Stage pT1bN0 Cutaneous Melanoma: Prognostic Factors and Risk Groups

Nivolumab Delivered Through Continuous Intrathecal Infusion for Advanced Melanoma

Long-Term Results With Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutated Melanoma